A Phase 2 interventional study of BGJ398 in Tumor-Induced Osteomalacia and Oncogenic Osteomalacia, sponsored by National Institute of Dental and Craniofacial Research (NIDCR). Terminated at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by National Institute of Dental and Craniofacial Research (NIDCR) · Phase 2, Interventional, and Treatment
Background:
People with tumor-induced osteomalacia (TIO) have small tumors that may cause low blood phosphorus, weak muscles, bone pain, and broken bones. The tumors may be so small they are hard to find or impossible to remove. Researchers want to test a drug that may help treat TIO.
Objective:
To see how the drug BGJ398 affects people with tumor-induced osteomalacia.
Eligibility:
People ages 18-85 who are in NIH protocol 01-D-0184 and have TIO that cannot be found or easily removed
Design:
At every study visit, participants will have:
At the screening visit, participants will also have a heart and eye tests. They may have other tests to find their tumor.
The baseline visit will be a 1-week stay in the clinic. Participants will have the regular study tests, plus:
Participants will take the study drug for six 1-month cycles. In each cycle, participants will:
Participants will have 1 visit at the end of the last cycle and another 3 months later....
Background:
Objectives:
To induce complete metabolic response in subjects with tumor-induced osteomalacia (TIO) with BGJ-398 as demonstrated by normalization of FGF23 and phosphate homeostasis.
Eligibility:
Patients may be eligible if they:
Design:
53 studies on the registry are indexed under Hypophosphatemia; 16 are open to participants now.
This study's enrollment of 4 is below the median of 46 across 26 interventional studies indexed under Hypophosphatemia.
Browse Hypophosphatemia studies →National Institute of Dental and Craniofacial Research (NIDCR) is the lead sponsor of 94 studies on the registry; 9 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients eligible for inclusion in this study have to meet all of the following criteria:
EXCLUSION CRITERIA:
Patients eligible for this study must not meet any of the following criteria:
Insufficient bone marrow function defined as all of the following:
Insufficient hepatic and renal function defined as one of the following:
cardiac disease including any of the following:
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 3 months following the discontinuation of study treatment. Highly effective contraception methods include:
Combination of the following (a+b or a+c, or b+c):
Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
Drug: BGJ398
BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
Number of Participants With Complete Metabolic Remission After Stopping BGJ398
Participants were monitored for up to 12 weeks after stopping BGJ398. A participant was considered to have a complete metabolic remission by achieving both normal blood FGF23 and phosphorus levels in the blood for 12 weeks after stopping BGJ398.
Time frame: Up to 12 weeks after stopping BGJ398
Number of Participants With Complete and Partial Metabolic Response Rate
Participants were monitored for metabolic response to BGJ398 every other week. A participant was considered to have a complete metabolic response by achieving both normal c-terminal FGF23 and phosphorus levels at each time point. A participant was considered to have a partial metabolic response by achieving both a decrease of at least 50% in c-terminal FGF23 levels and an increase of at least 50% in phosphorous at each time point
Time frame: Every 2 weeks up to 24 weeks
Number of Participants With Grade 3 or 4 Adverse Events or Serious Adverse Events
Percentage of patients who incurred grade 3 or 4 adverse events (AEs) or serious adverse events (SAE) or AEs causing dose interruption/reduction
Time frame: 24 week treatment phase followed by 3 month follow up or extension phase
Six-Minute Walk Test
The Six-Minute Walk Test (6MWT), is a self-paced practical test that measures the distance the patient can quickly cover on a flat, hard surface. Each subject was instructed to complete the maximum distance possible in six minutes. Feedback was given in two minute intervals and during the last 30 seconds. Patients were instructed to notify test administrator of leg cramping, pain, nausea, dizziness and shortness of breath. Test administrators counted each lap and upon test completion, the partial distance is measured and added to where the subject stopped.
Time frame: Assessed at baseline and 24 weeks after starting BGJ398
Hand Grip Strength Test
The person is seated, lower extremities flexed at 90 degrees. The individual uses the dominant hand for this activity. The individual sit with shoulder adducted and neutrally rotated elbow flexed at 90 degrees, forearm in neutral position, resting on the arm of a chair. The JAMAR Hand Dynamometer set to the third level position from the inside is used. The examiner lightly supports the readout dial to prevent it from dropping. The patient is asked to "Squeeze as hard as you can….squeeze…..squeeze….relax." Three successive trials is recorded in kilograms. A 10-15 second break occurs to prevent muscle fatigue. Scores are recorded and averaged for the final result. Scores within two standard deviations of the mean are considered within normal limits.
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Pinch Test
A lateral pinch is required of the patient, using the dominant hand. The individual is seated, lower extremities flexed at 90 degrees. The examiner stabilizes the patient's wrist as the patient holds the pinch gauge to perform the test. The examiner requests the person to pinch with maximum strength. The peak-hold needle will automatically record the highest force exerted. After the patient uses the Pinch gauge, the examiner records the reading and resets the peak-hold needle to zero before testing again. Three lateral pinch trials are recorded and averaged for the final result.
Time frame: Assessed at baseline and every 4 weeks for the 24 treatment period, and every 4 weeks in the follow up phase, up to 37 weeks
Five Times Sit-to-Stand Test
The Five Times Sit to Stand Test measures an aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. The chair is free standing. Patient sits with arms folded across chest and with their back against the chair. A standard chair height 44 cm was used for each patient. Patient stands fully between repetitions of the test, careful to not touch the back of the chair during each repetition. Patient instructions: "I want you to stand up and sit down 5 times as quickly as you can when I say Go." Timing begins at "Go" and ends when the buttocks touches the chair after the 5th repetition. The results are recorded in seconds.
Time frame: Assessed at baseline and every 4 weeks during the 24 week treatment period
The Disabilities of Arm Shoulder and Hand Outcome Measurement (DASH)
The Disabilities of Arm Shoulder and Hand Outcome Measurement (DASH) The minimum score value is 0, maximum is 100, where a higher school represents a worse outcome (significant symptoms/disability)
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
RAND SF-36 Survey Results
Evaluation using the RAND 36-Item Short Form Survey (SF-36). Results were separated into 8 domains - Physical Functioning, Role limitations due to physical health problems, Role limitations due to emotional problems, Emotional well-being, Energy/fatigue, Social functioning, Bodily Pain, and General health perceptions. The minimum value is 0, the maximum value is 100, which the higher the score, the better the outcome.
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
PROMIS Fatigue
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue 8A short form. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents increased feelings of fatigue.
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
PROMIS Pain Interference Score
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference 8A short form. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents increased pain interference
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
PROMIS Mobility Score
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Mobility bank. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents a better outcome (unencumbered mobility)
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Blood Intact FGF23 Levels
Measured Blood Intact FGF23 Levels.
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Blood C-terminal FGF23 Level
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Blood Phosphate Levels
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Blood 1,25-(OH)2-Vitamin D Level
Time frame: Assessed at baseline and every 4 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Blood Alkaline Phosphatase
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Tubular Reabsorption of Phosphate
Tubular Reabsorption of Phosphate was calculated using blood phosphate and creatinine, as well as either 24 hour urine or spot urine samples.
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Tubular Maximum Reabsorption Rate of Phosphate to Glomerular Filtration Rate (TmP/GFR)
Tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) was calculated using blood phosphate and creatinine, as well as either 24 hour urine or spot urine samples.
Time frame: Assessed at baseline and every 2 weeks up to 24 weeks during the treatment phase, and every 4 weeks in the follow up phase, up to 37 weeks
Radiographic Evidence of Tumor-Induced Osteomalacia
In patients with radiographic evidence of TIO, 18FDG PET scans were performed
Time frame: Baseline and at 24 weeks
| Milestone | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Started | 4 |
| Treated | 4 |
| Extension phase | 1 |
| Screening failures | 0 |
| Completed | 3 |
| Not completed | 1 |
| Withdrew: Physician decision | 1 |
Participants were monitored for up to 12 weeks after stopping BGJ398. A participant was considered to have a complete metabolic remission by achieving both normal blood FGF23 and phosphorus levels in the blood for 12 weeks after stopping BGJ398.
| Participants | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Complete Metabolic Remission | 0 |
| No Complete Metabolic Remission | 4 |
Participants were monitored for metabolic response to BGJ398 every other week. A participant was considered to have a complete metabolic response by achieving both normal c-terminal FGF23 and phosphorus levels at each time point. A participant was considered to have a partial metabolic response by achieving both a decrease of at least 50% in c-terminal FGF23 levels and an increase of at least 50% in phosphorous at each time point
| Participants | Single Arm (TIO Subjects) |
|---|---|
| Baseline — Complete Metabolic Response | 0 |
| Baseline — Partial Metabolic Response | 0 |
| Baseline — Neither Complete or Partial Metabolic Response | 4 |
| Week 2 — Complete Metabolic Response | 2 |
| Week 2 — Partial Metabolic Response | 1 |
| Week 2 — Neither Complete or Partial Metabolic Response | 1 |
| Week 4 — Complete Metabolic Response | 0 |
| Week 4 — Partial Metabolic Response | 1 |
| Week 4 — Neither Complete or Partial Metabolic Response | 3 |
| Week 6 — Complete Metabolic Response | 2 |
| Week 6 — Partial Metabolic Response | 1 |
| Week 6 — Neither Complete or Partial Metabolic Response | 1 |
| Week 8 — Complete Metabolic Response | 1 |
| Week 8 — Partial Metabolic Response | 1 |
| Week 8 — Neither Complete or Partial Metabolic Response | 2 |
| Week 10 — Complete Metabolic Response | 0 |
| Week 10 — Partial Metabolic Response | 0 |
| Week 10 — Neither Complete or Partial Metabolic Response | 4 |
| Week 12 — Complete Metabolic Response | 1 |
| Week 12 — Partial Metabolic Response | 1 |
| Week 12 — Neither Complete or Partial Metabolic Response | 2 |
| Week 14 — Complete Metabolic Response | 1 |
| Week 14 — Partial Metabolic Response | 1 |
| Week 14 — Neither Complete or Partial Metabolic Response | 2 |
| Week 16 — Complete Metabolic Response | 0 |
| Week 16 — Partial Metabolic Response | 1 |
| Week 16 — Neither Complete or Partial Metabolic Response | 3 |
| Week 18 — Complete Metabolic Response | 1 |
| Week 18 — Partial Metabolic Response | 2 |
| Week 18 — Neither Complete or Partial Metabolic Response | 1 |
| Week 20 — Complete Metabolic Response | 1 |
| Week 20 — Partial Metabolic Response | 1 |
| Week 20 — Neither Complete or Partial Metabolic Response | 2 |
| Week 22 — Complete Metabolic Response | 1 |
| Week 22 — Partial Metabolic Response | 1 |
| Week 22 — Neither Complete or Partial Metabolic Response | 2 |
| Week 24 - prior to drug discontinuation — Complete Metabolic Response | 0 |
| Week 24 - prior to drug discontinuation — Partial Metabolic Response | 0 |
| Week 24 - prior to drug discontinuation — Neither Complete or Partial Metabolic Response | 4 |
| Week 24 - after drug discontinuation — Complete Metabolic Response | 0 |
| Week 24 - after drug discontinuation — Partial Metabolic Response | 0 |
| Week 24 - after drug discontinuation — Neither Complete or Partial Metabolic Response | 4 |
Percentage of patients who incurred grade 3 or 4 adverse events (AEs) or serious adverse events (SAE) or AEs causing dose interruption/reduction
| Participants | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| SAE | 0 |
| Grade 4 AE | 0 |
| Grade 3 AE | 1 |
| AE leading to dose interruption/reduction | 4 |
The Six-Minute Walk Test (6MWT), is a self-paced practical test that measures the distance the patient can quickly cover on a flat, hard surface. Each subject was instructed to complete the maximum distance possible in six minutes. Feedback was given in two minute intervals and during the last 30 seconds. Patients were instructed to notify test administrator of leg cramping, pain, nausea, dizziness and shortness of breath. Test administrators counted each lap and upon test completion, the partial distance is measured and added to where the subject stopped.
| Meters | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 320.4 ± 221.8 |
| 24 Weeks | 496 ± 173.4 |
The person is seated, lower extremities flexed at 90 degrees. The individual uses the dominant hand for this activity. The individual sit with shoulder adducted and neutrally rotated elbow flexed at 90 degrees, forearm in neutral position, resting on the arm of a chair. The JAMAR Hand Dynamometer set to the third level position from the inside is used. The examiner lightly supports the readout dial to prevent it from dropping. The patient is asked to "Squeeze as hard as you can….squeeze…..squeeze….relax." Three successive trials is recorded in kilograms. A 10-15 second break occurs to prevent muscle fatigue. Scores are recorded and averaged for the final result. Scores within two standard deviations of the mean are considered within normal limits.
| kg | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 14.7 ± 11.8 |
| Week 4 | 16.4 ± 11.2 |
| Week 8 | 18.5 ± 9.4 |
| Week 12 | 17.0 ± 7.9 |
| Week 16 | 22.6 ± 18.5 |
| Week 20 | 17.3 ± 6.6 |
| Week 24 | 15.5 ± 1.4 |
| Week 28 | 30.1 ± 6.7 |
A lateral pinch is required of the patient, using the dominant hand. The individual is seated, lower extremities flexed at 90 degrees. The examiner stabilizes the patient's wrist as the patient holds the pinch gauge to perform the test. The examiner requests the person to pinch with maximum strength. The peak-hold needle will automatically record the highest force exerted. After the patient uses the Pinch gauge, the examiner records the reading and resets the peak-hold needle to zero before testing again. Three lateral pinch trials are recorded and averaged for the final result.
| kg | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 6.8 ± 4.0 |
| Week 4 | 6.7 ± 1.2 |
| Week 8 | 6.8 ± 1.3 |
| Week 12 | 7.5 ± 2.0 |
| Week 16 | 7.5 ± 1.0 |
| Week 20 | 7.7 ± 1.5 |
| Week 24 | 7.0 ± 1.3 |
| Week 28 | 8.1 ± 1.9 |
The Five Times Sit to Stand Test measures an aspect of transfer skill. The test provides a method to quantify functional lower extremity strength and/or identify movement strategies a patient uses to complete transitional movements. The chair is free standing. Patient sits with arms folded across chest and with their back against the chair. A standard chair height 44 cm was used for each patient. Patient stands fully between repetitions of the test, careful to not touch the back of the chair during each repetition. Patient instructions: "I want you to stand up and sit down 5 times as quickly as you can when I say Go." Timing begins at "Go" and ends when the buttocks touches the chair after the 5th repetition. The results are recorded in seconds.
| seconds | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 14.7 ± 6.5 |
| Week 4 | 13.2 ± 4.0 |
| Week 8 | 13.5 ± 1.1 |
| Week 12 | 11.2 ± 0.7 |
| Week 16 | 10.5 ± 1.5 |
| Week 20 | 10.8 ± 0.8 |
| Week 24 | 11.1 ± 0.8 |
| Week 28 | 11.1 ± 1.0 |
The Disabilities of Arm Shoulder and Hand Outcome Measurement (DASH) The minimum score value is 0, maximum is 100, where a higher school represents a worse outcome (significant symptoms/disability)
| DASH Disability/Symptom Score | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 16.5 ± 4.8 |
| Week 4 | 13.3 ± 6.8 |
| Week 8 | 14.2 ± 4.6 |
| Week 12 | 13.3 ± 7.3 |
| Week 16 | 12.7 ± 6.7 |
| Week 20 | 21.0 ± 23.1 |
| Week 24 | 12.1 ± 8.1 |
| Week 28 | 10.0 ± 2.3 |
Evaluation using the RAND 36-Item Short Form Survey (SF-36). Results were separated into 8 domains - Physical Functioning, Role limitations due to physical health problems, Role limitations due to emotional problems, Emotional well-being, Energy/fatigue, Social functioning, Bodily Pain, and General health perceptions. The minimum value is 0, the maximum value is 100, which the higher the score, the better the outcome.
| score on a scale | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Physical Functioning - Baseline | 46.3 ± 18.9 |
| Physical Functioning - 4 weeks | 47.5 ± 21.0 |
| Physical Functioning - 8 weeks | 51.3 ± 16.5 |
| Physical Functioning - 12 weeks | 47.5 ± 12.6 |
| Physical Functioning - 16 weeks | 56.0 ± 16.2 |
| Physical Functioning - 20 weeks | 52.5 ± 26.0 |
| Physical Functioning - 24 weeks | 41.0 ± 6.4 |
| Physical Functioning - 28 weeks | 65.0 ± 7.1 |
| Role limitations due to physical health problems - Baseline | 43.8 ± 12.5 |
| Role limitations due to physical health problems - 4 weeks | 93.8 ± 12.5 |
| Role limitations due to physical health problems - 8 weeks | 68.8 ± 31.5 |
| Role limitations due to physical health problems - 12 weeks | 50 ± 35.4 |
| Role limitations due to physical health problems - 16 weeks | 50 ± 57.7 |
| Role limitations due to physical health problems - 20 weeks | 75 ± 50 |
| Role limitations due to physical health problems - 24 weeks | 25 ± 50 |
| Role limitations due to physical health problems - 28 weeks | 12.5 ± 17.7 |
| Role limitations due to emotional problems - Baseline | 66.7 ± 27.2 |
| Role limitations due to emotional problems - 4 weeks | 83.3 ± 33.3 |
| Role limitations due to emotional problems - 8 weeks | 75 ± 31.9 |
| Role limitations due to emotional problems - 12 weeks | 66.7 ± 47.1 |
| Role limitations due to emotional problems - 16 weeks | 50 ± 43 |
| Role limitations due to emotional problems - 20 weeks | 91.7 ± 16.7 |
| Role limitations due to emotional problems - 24 weeks | 41.7 ± 50 |
| Role limitations due to emotional problems - 28 weeks | 33.3 ± 47.1 |
| Emotional well-being - Baseline | 67 ± 15.1 |
| Emotional well-being - 4 weeks | 72 ± 15.7 |
| Emotional well-being - 8 weeks | 72 ± 12.6 |
| Emotional well-being - 12 weeks | 72 ± 17.6 |
| Emotional well-being - 16 weeks | 69.8 ± 21.5 |
| Emotional well-being - 20 weeks | 73 ± 8.2 |
| Emotional well-being - 24 weeks | 62 ± 10.1 |
| Emotional well-being - 28 weeks | 72 ± 5.7 |
| Energy/fatigue - Baseline | 50 ± 29.4 |
| Energy/fatigue - Week 4 | 58.8 ± 8.5 |
| Energy/fatigue - week 8 | 52.5 ± 22.2 |
| Energy/fatigue - week 12 | 46.3 ± 28.4 |
| Energy/fatigue - week 16 | 61.3 ± 31.5 |
| Energy/fatigue - week 20 | 57.5 ± 18.5 |
| Energy/fatigue - week 24 | 48.8 ± 33.3 |
| Energy/fatigue - week 28 | 47.5 ± 53.0 |
| Social functioning - Baseline | 59.4 ± 37.3 |
| Social functioning - 4 weeks | 87.5 ± 14.4 |
| Social functioning - 8 weeks | 78.1 ± 21.3 |
| Social functioning - 12 weeks | 81.3 ± 16.1 |
| Social functioning - 16 weeks | 75 ± 27 |
| Social functioning - 20 weeks | 78.1 ± 25.8 |
| Social functioning - 24 weeks | 71.9 ± 32.9 |
| Social functioning - 28 weeks | 75 ± 17.7 |
| Bodily Pain - Baseline | 51.9 ± 29.2 |
| Bodily Pain - week 4 | 66.3 ± 28 |
| Bodily Pain - week 8 | 63.1 ± 37.4 |
| Bodily Pain - week 12 | 43.1 ± 26.8 |
| Bodily Pain - week 16 | 72.5 ± 34.6 |
| Bodily Pain - week 20 | 75 ± 20.7 |
| Bodily Pain - week 24 | 36.2 ± 2.5 |
| Bodily Pain - week 28 | 90 ± 0 |
| General health perceptions - Baseline | 60 ± 10.8 |
| General health perceptions - week 4 | 68.8 ± 13.1 |
| General health perceptions - week 8 | 72.5 ± 16.6 |
| General health perceptions - week 12 | 73.8 ± 25.9 |
| General health perceptions - week 16 | 71.3 ± 14.9 |
| General health perceptions - week 20 | 67.5 ± 23.3 |
| General health perceptions - week 24 | 71.3 ± 18.0 |
| General health perceptions - week 28 | 67.5 ± 31.8 |
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue 8A short form. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents increased feelings of fatigue.
| T score | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 55.1 ± 8.1 |
| Week 4 | 47.4 ± 1.6 |
| Week 8 | 52.6 ± 7.9 |
| Week 12 | 52.3 ± 9.1 |
| Week 16 | 52.3 ± 9.1 |
| Week 20 | 46.6 ± 9.1 |
| Week 24 | 52 ± 4.9 |
| Week 28 | 46.7 ± 8.1 |
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference 8A short form. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents increased pain interference
| T score | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 56.4 ± 4.5 |
| Week 4 | 52.6 ± 9.4 |
| Week 8 | 52.5 ± 6.0 |
| Week 12 | 55.7 ± 4.2 |
| Week 16 | 49.0 ± 10.6 |
| Week 20 | 48.2 ± 15 |
| Week 24 | 52.6 ± 9.1 |
| Week 28 | 40.7 ± 0 |
Assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Mobility bank. Scores are given as T values when compared to a population where the mean is 50 and 1SD is 10. A higher score represents a better outcome (unencumbered mobility)
| T score | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 38.2 ± 6.7 |
| Week 4 | 40.0 ± 6.4 |
| Week 8 | 39.3 ± 5.3 |
| Week 12 | 38.8 ± 3.2 |
| Week 16 | 40.2 ± 4.5 |
| Week 20 | 40.7 ± 7.3 |
| Week 24 | 39.5 ± 2.6 |
| Week 28 | 43.6 ± 1.6 |
Measured Blood Intact FGF23 Levels.
| pg/mL | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 1384 ± 1467 |
| 4 Weeks | 282 ± 254 |
| 8 Weeks | 286 ± 236 |
| 12 Weeks | 596 ± 924 |
| 16 Weeks | 310 ± 202 |
| 20 Weeks | 135 ± 67 |
| 24 Weeks | 439 ± 230 |
| Follow up | 2534.8 ± 2824.6 |
| RU/mL | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 814 ± 911 |
| 2 Weeks | 213 ± 158 |
| 4 Weeks | 330 ± 87 |
| 6 Weeks | 229 ± 123 |
| 8 Weeks | 304 ± 154 |
| 10 Weeks | 2225 ± 2015 |
| 12 Weeks | 430 ± 409 |
| 14 Weeks | 270 ± 65 |
| 16 Weeks | 360 ± 75 |
| 18 Weeks | 185 ± 151 |
| 20 Weeks | 274 ± 118 |
| 22 Weeks | 368 ± 272 |
| 24 Weeks | 463 ± 102 |
| Follow up | 1568 ± 1863 |
| mg/dL | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 1.6 ± 0.3 |
| Week 2 | 2.7 ± 0.9 |
| Week 4 | 2.9 ± 1 |
| Week 6 | 3.2 ± 1.3 |
| Week 8 | 3.6 ± 1.5 |
| Week 10 | 3.1 ± 0.7 |
| Week 12 | 2.9 ± 1.2 |
| Week 14 | 2.8 ± 1.2 |
| Week 16 | 3.4 ± 1.6 |
| Week 18 | 2.5 ± 0.2 |
| Week 20 | 3.0 ± 1.3 |
| Week 22 | 3.3 ± 2.8 |
| Week 24 | 3.0 ± 1.2 |
| Follow up | 2.3 ± 0.4 |
| pg/mL | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 22.5 ± 16.1 |
| Week 2 | 112.3 ± 94.5 |
| Week 4 | 79 ± 68.4 |
| Week 6 | 202.8 ± 246.5 |
| Week 8 | 64.7 ± 30.7 |
| Week 10 | 85.7 ± 63.8 |
| Week 12 | 96.5 ± 61.4 |
| Week 14 | 59.8 ± 28.9 |
| Week 16 | 36 ± 6.1 |
| Week 18 | 86.5 ± 56.3 |
| Week 20 | 33 ± 12.1 |
| Week 22 | 22.5 ± 19.1 |
| Week 24 | 80.3 ± 35.7 |
| Follow up | 51 ± 32.2 |
| IU/L | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 132 ± 52.3 |
| Week 2 | 178.8 ± 50.7 |
| Week 4 | 186.5 ± 42.1 |
| Week 6 | 198 ± 36.6 |
| Week 8 | 171.8 ± 26.6 |
| Week 10 | 181.3 ± 22 |
| Week 12 | 170 ± 18.4 |
| Week 14 | 188.3 ± 29.4 |
| Week 16 | 175.5 ± 14.3 |
| Week 18 | 183 ± 40.4 |
| Week 20 | 190.3 ± 33.6 |
| Week 22 | 200.7 ± 48 |
| Week 24 | 192.3 ± 67.4 |
| Follow up | 185.7 ± 17 |
Tubular Reabsorption of Phosphate was calculated using blood phosphate and creatinine, as well as either 24 hour urine or spot urine samples.
| % Filtered Phosphate | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 67 ± 20 |
| Week 2 | 82 ± 13 |
| Week 4 | 79 ± 14 |
| Week 6 | 84 ± 14 |
| Week 8 | 78 ± 19 |
| Week 10 | 50 ± 36 |
| Week 12 | 45 ± 36 |
| Week 14 | 82 ± 15 |
| Week 16 | 81 ± 15 |
| Week 18 | 77 ± 13 |
| Week 20 | 75 ± 12 |
| Week 22 | 81 ± 11 |
| Week 24 | 74 ± 19 |
Tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) was calculated using blood phosphate and creatinine, as well as either 24 hour urine or spot urine samples.
| mg/dL | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline | 1.1 ± 0.5 |
| Week 2 | 2.5 ± 1.2 |
| Week 4 | 2.3 ± 1.3 |
| Week 6 | 3.5 ± 2.2 |
| Week 8 | 3.4 ± 2.3 |
| Week 10 | 1.32 ± 0.9 |
| Week 12 | 1.52 ± 1.86 |
| Week 14 | 2.76 ± 1.61 |
| Week 16 | 3.44 ± 2.47 |
| Week 18 | 1.98 ± 0.34 |
| Week 20 | 2.31 ± 1.25 |
| Week 22 | 3.86 ± 2.99 |
| Week 24 | 2.61 ± 1.87 |
In patients with radiographic evidence of TIO, 18FDG PET scans were performed
| Units | TIO Subjects With Radiographic Evidence of TIO Who Received BGJ398 (Single Arm) |
|---|---|
| Baseline SUVmax Tumor | 7.9 ± 1.3 |
| 24 Week SUVmax tumor | 3.9 ± 1.3 |
Collected over Patients were monitored for adverse events during 24 weeks of treatment followed by 3 month follow-up period, with optional extension phase up to 37 weeks. If a patient was withdrawn from the study, adverse event data was no longer collected. Subjects who required permanent discontinuation of BGJ398 therapy due to an adverse event continued to be followed in the study until the toxicity had resolved or up to 30 days after study drug discontinuation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TIO Subjects Who Received BGJ398 (Single Arm) | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | TIO Subjects Who Received BGJ398 (Single Arm) |
|---|---|
| Blurred visionEye disorders | 4/4 |
| Corneal inflamation/keratitisEye disorders | 4/4 |
| Pain, nailsSkin and subcutaneous tissue disorders | 4/4 |
| Nail change/separationSkin and subcutaneous tissue disorders | 4/4 |
| Dry eyeEye disorders | 3/4 |
| Lymphocyte count decreasedInvestigations | 3/4 |
| Parathyroid hormone increasedInvestigations | 3/4 |
| HyperphosphatemiaInvestigations | 3/4 |
| Dry mouthGastrointestinal disorders | 3/4 |
| Pain, musculoskeletalMusculoskeletal and connective tissue disorders | 3/4 |
| Age, Categorical(Participants) | Single Arm (TIO Subjects) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 0 |
| Age, Continuous(years) | Single Arm (TIO Subjects) |
|---|---|
| Mean | 33.75 ± 7.8 |
| Sex: Female, Male(Participants) | Single Arm (TIO Subjects) |
|---|---|
| Female | 2 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm (TIO Subjects) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 4 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Single Arm (TIO Subjects) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Type of TIO Disease(Participants) | Single Arm (TIO Subjects) |
|---|---|
| Localized | 2 |
| Non-localized | 2 |
| Metastatic | 0 |
| Blood Intact FGF23 on Initiation of Study(pg/mL) | Single Arm (TIO Subjects) |
|---|---|
| Mean | 1384 ± 1467 |
| Blood C-Terminal FGF23 on Initiation of Study(RU/mL) | Single Arm (TIO Subjects) |
|---|---|
| Mean | 814 ± 911 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
National Institute of Dental and Craniofacial Research (NIDCR) →